搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
9 小时
on MSN
Novo Nordisk CEO says he's confident about Wegovy supply, next-generation weight loss drugs
Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.
13 小时
on MSN
Novo Nordisk Stock Jumps After Earnings. The Weight-Loss Drugmaker Has Growth Concerns.
The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...
16 小时
Novo Nordisk defends next-gen obesity drug CagriSema, gives details of new trial
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
3 天
on MSN
Forget Wegovy: Novo Nordisk May Have a New Billion-Dollar Weight Loss Drug On Its Hands
In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...
6 小时
Weight loss pill could replace injections, would be transformative for millions
While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...
1 天
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
20 小时
on MSN
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...
7 小时
Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations
Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...
18 小时
Novo Nordisk Q4 Earnings: Wegovy Sales More Than Double, Seeks Regulatory Approval For ...
Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...
12 天
on MSN
Novo Nordisk Stock Jumps on Early Stage Weight-Loss Drug Trial Results
Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...
1 天
Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema ...
Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.
14 小时
Novo Nordisk beats on Wegovy sales, expects slower 2025 growth
Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果
反馈